CRISPR Therapeutics AG

Listed Company

CRSPCIK 0001674416NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)V8CHFY ends Dec 31

Period

FY 2025

Revenue

$3.51M

Net Income

$-581.60M

Total Assets

$2.27B

Equity

$1.92B

Shares Out

95.99M

Op. Cash Flow

$-345.01M

Business

CRISPR Therapeutics AG is a gene editing company developing CRISPR/Cas9‑based therapeutics to treat serious human diseases. It develops ex vivo and in vivo gene‑edited medicines and engineered cell therapies, including the approved exa‑cel (CASGEVY), next‑generation allogeneic CAR T candidates, liver‑directed in vivo programs (e.g., CTX310, CTX320), and gene‑edited stem cell‑derived approaches for type 1 diabetes. Its business is organized across four core franchises: hemoglobinopathies, CAR T, in vivo approaches and type 1 diabetes, plus early‑stage CRISPR‑X research. CRISPR distributes clinical and potential commercial products through strategic partnerships, internal GMP manufacturing and third‑party contract manufacturers across the U.S., Europe and other global markets.

Summary from filing dated 2025-02-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	4	37	371	1	915
Research and development	285	310	387	462	341
Acquired in-process research and development	96	0	0	—	—
General and administrative	74	73	76	102	100
Collaboration expense, net	213	121	130	110	101
Total operating expenses	668	504	594	674	541
Loss from operations	−665	−467	−223	−673	374
Other income, net	87	104	72	23	6
Total other income, net	87	104	72	23	6
Net loss before income taxes	−578	−363	−151	−651	380
Provision for income taxes	−4	−4	−3	325,000	−2
Net loss	−582	−366	−154	−650	378
Foreign currency translation adjustment	95,000	−21,000	73,000	−80,000	−11,000
Unrealized gain (loss) on marketable securities	3	−52,000	17	−11	−5
Comprehensive loss	−579	−366	−136	−661	373
Net loss per common share - basic	−6.47	−4.34	−1.94	−8.36	4.97
Basic weighted-average common shares outstanding	90	84	79	78	76
Net loss per common share - diluted	−6.47	−4.34	−1.94	−8.36	4.7
Diluted weighted-average common shares outstanding	90	84	79	78	80

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	348	298	389	212	923
Marketable securities	1,628	1,606	1,304	1,603	1,456
Accounts receivable	0	25	200	0	305,000
Prepaid expenses and other current assets	10	8	14	38	38
Total current assets	1,986	1,937	1,908	1,853	2,418
Property and equipment, net	116	134	152	164	138
Restricted cash	8	12	12	12	17
Operating lease assets	132	143	154	157	174
Other non-current assets	24	16	2	5	5
Total assets	2,265	2,242	2,230	2,243	2,752
Accounts payable	11	15	38	27	15
Accrued expenses	89	41	45	78	91
Deferred revenue, current	16	4	4	0	1
Accrued tax liabilities	1	451,000	438,000	135,000	724,000
Operating lease liabilities	19	17	16	16	12
Other current liabilities	13	10	5	20,000	171,000
Total current liabilities	149	88	109	121	120
Deferred revenue, non-current	0	12	14	12	12
Operating lease liabilities, net of current portion	188	206	223	228	213
Other non-current liabilities	6	3	958,000	6	7
Total liabilities	343	310	347	368	352
Commitments and contingencies (Note 9)	—	—	—	—	—
Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at December 31, 2025 and December 31, 2024, 96,009,657 and 85,912,297 shares issued at December 31, 2025 and December 31, 2024, respectively, 95,894,341 and 85,741,981 shares outstanding at December 31, 2025 and December 31, 2024, respectively	3	3	2	2	2
Treasury shares, at cost, 115,316 and 170,316 shares at December 31, 2025 and December 31, 2024, respectively	−60,000	−62,000	−62,000	−63,000	−63,000
Additional paid-in capital	3,862	3,294	2,878	2,735	2,598
Accumulated deficit	−1,948	−1,366	−1,000	−846	−196
Accumulated other comprehensive income	5	2	2	−16	−5
Total shareholders equity	1,922	1,932	1,883	1,875	2,399
Total liabilities and shareholders equity	2,265	2,242	2,230	2,243	2,752

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−582	−366	−154	−650	378
Depreciation and amortization	19	19	20	24	18
Stock-based compensation expense	72	87	81	98	102
Other non-cash items, net	−24	−39	−17	12	14
Acquired in-process research and development	—	—	3	—	—
Accounts receivable	25	175	−200	305,000	−161,000
Prepaid expenses and other assets	3	5	23	2	−14
Accounts payable and accrued expenses	45	−27	−20	5	38
Deferred revenue	−397,000	−2	6	−1	−783,000
Operating lease assets and liabilities	−5	−4	−2	15	10
Other liabilities, net	4	10	110,000	−2	−5
Net cash used in operating activities	−345	−143	−260	−496	539
Purchase of property, plant and equipment	−914,000	−2	−9	−37	−82
Purchase of in-process research and development	−25	0	−3	0	0
Investment in equity securities	−10	−23	0	0	—
Sale of equity securities	702,000	0	0	—	—
Purchases of marketable debt securities	−1,008	−1,463	−1,066	−1,418	−1,509
Maturities of marketable debt securities	1,011	1,208	1,453	1,196	556
Net cash used in (provided by) investing activities	−32	−280	375	−259	−1,035
Proceeds from issuance of common shares, net of issuance costs	398	301	33	970,000	213
Proceeds from exercise of options and ESPP contributions, net of issuance costs	28	31	30	38	38
Net cash provided by financing activities	426	332	63	39	251
Effect of exchange rate changes on cash	95,000	−21,000	73,000	−80,000	−11,000
Increase (decrease) in cash	49	−91	177	−716	−246
Property and equipment purchases in accounts payable and accrued expenses	394,000	154,000	725,000	2	8
Equity issuance costs in accounts payable and accrued expenses	5	3	417,000	99,000	334,000
Acquired in-process research and development expense related to issuance of common shares	71	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro